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Abstract
Background: Hyperglycemia is a frequent phenomenon in hospitalized patients that is associ-
ated with negative outcomes. It is common in liver transplant patients as a result of stress and
is related to immunosuppressant drugs. Although studies are few, a history of diabetes and the
presentation of hyperglycemia during liver transplantation have been associated with a higher
risk for rejection.
Aims: To analyze whether hyperglycemia during the ﬁrst 48 hours after liver transplantation
was associated with a higher risk for infection, rejection, or longer hospital stay.
Methods: A retrospective cohort study was conducted on patients above the age of 15 years that
received a liver transplant. Hyperglycemia was deﬁned as a value above 140mg/dl and it was
measured in three different manners (as an isolated value, as a mean value, and as a weighted
value over time). The relation of hyperglycemia to a risk for acute rejection, infection, or
longer hospital stay was evaluated.
Results: Some form of hyperglycemia was present in 94% of the patients during the ﬁrst 48 post-
transplantation hours, regardless of its deﬁnition. There was no increased risk for rejection (OR:
1.49; 95%CI: 0.55-4.05), infection (OR: 0.62; 95%CI: 0.16-2.25), or longer hospital stay between
the patients that presented with hyperglycemia and those that did not.
 Please cite this article as: Builes Montan˜o CE, Montoya JF, Aguilar London˜o C, Palacios Bayona KL, Restrepo Gutiérrez JC, Restrepo
G, et al. Complicaciones asociadas a la hiperglucemia en pacientes trasplantados de hígado. Revista de Gastroenterología de México.
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Conclusions: Hyperglycemia during the ﬁrst 48 hours after transplantation appeared to be an
expected phenomenon in the majority of patients and was not associated with a greater risk
for rejection or infection and it had no impact on the duration of hospital stay.
© 2014 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. All
rights reserved.
PALABRAS CLAVE
Trasplante hepático;
Rechazo del injerto;
Hiperglucemia
Complicaciones asociadas a la hiperglucemia en pacientes trasplantados de hígado
Resumen
Antecedentes: La hiperglucemia es un fenómeno frecuente en los pacientes hospitalizados aso-
ciado a desenlaces negativos, y es frecuente en los pacientes trasplantados de hígado como
un fenómeno de estrés y asociada a medicamentos inmunosupresores. Aunque los estudios son
escasos, el antecedente de diabetes, así como la hiperglucemia durante el trasplante hepático,
se han asociado con mayor riesgo de rechazo.
Objetivo: Estudiar si la hiperglucemia durante las primeras 48 h después de un trasplante
hepático se asocia a un mayor riesgo de infección, rechazo o estancia hospitalaria.
Métodos: Estudio de cohorte de tipo retrospectivo en pacientes mayores de 15 an˜os que reci-
bieron un trasplante hepático. Se deﬁnió la hiperglucemia como un valor superior a 140mg/dl
y se midió de 3 maneras diferentes (como un valor aislado, como la media de los valores y
como un valor ponderado en el tiempo) y se analizó su relación con el riesgo de rechazo agudo,
infección y tiempo de estancia hospitalaria.
Resultados: Un 94% de los pacientes presentó alguna forma de hiperglucemia durante las
primeras 48 h postrasplante independientemente de cómo esta fue deﬁnida, y no hubo un mayor
riesgo de rechazo (OR: 1.49; IC 95%: 0.55-4.05), infección (OR: 0.62; IC 95%: 0.16-2.25) o tiempo
de estancia hospitalaria entre los pacientes que la presentaron y los que no.
Conclusión: La hiperglucemia durante las primeras 48 h después de un trasplante pareciera ser
un fenómeno esperable en la mayoría de pacientes y no se asocia a un mayor riesgo de rechazo,
infección y no impacta en el tiempo de estancia hospitalaria.
© 2014 Asociación Mexicana de Gastroenterología. Publicado por Masson Doyma México S.A.
Todos los derechos reservados.
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Hyperglycemia is deﬁned as any glucose value > 140mg/dl.1
It occurs in 32 to 38% of all hospitalized patients, 41% of all
the critically ill, 44% of patients with heart failure, and up to
80% of patients after cardiac surgery; between 30 and 80% of
those individuals have no history of diabetes.2 Stress hyper-
glycemia is that which presents in patients with no history
of diabetes and is usually transitory. It is caused by coun-
terregulatory hormones (such as cortisol and adrenaline)
and by the increase in insulin resistance,3,4 but the most
important factor appears to be hepatic gluconeogenesis.5
Hyperglycemia in the hospitalized patient, especially those
that have undergone transplantation, can also be the
consequence of the use of different types of medica-
tion, such as glucocorticoids and other immunosuppressant
drugs.6,7
The long-term deleterious effects of hyperglycemia are
well-known, especially those related to micro and macrovas-
cular damage.8,9 In the context of the acute patient,
hyperglycemia produces changes in the immune system10and coagulation.11 In addition, ﬂuctuations in glucose levels
induce apoptosis in the endothelial cells, causing endothe-
lial dysfunction. 12
a
hIn the patient with no history of diabetes, hyperglycemia
s a mortality marker, especially in those patients in inten-
ive care units (ICUs). It is also associated with longer
eriods of hospital stay and a greater risk for postoperative
nfection.13--15 Hyperglycemia has additionally been associ-
ted with adverse events in patients with acute myocardial
nfarction16--19 and with cerebrovascular disease (CVD).20,21
On the other hand, diabetes is a frequent comorbidity
n patients on the liver transplantation waiting list, pre-
enting in 65% of them.22 Despite this fact, there is scant
vidence that hyperglycemia is a risk factor for negative
utcomes in patients that have undergone transplantations,
ven though, in general, diabetes is associated with a worse
utcome in liver transplantation patients. The prevalence
f post-transplantation diabetes is as high as 31-38%,23
nd these patients are at a higher risk for cardiovascular
omplications, such as high blood pressure and coronary
isease, as well as a higher mortality rate, compared with
hose patients that do not develop diabetes.24,25 Likewise,
atients that develop post-transplantation diabetes have a
igher number of acute rejection episodes, and infectious
nd neurologic complications.26--28
Different mechanisms have been proposed by which
yperglycemia could produce graft damage and increase
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he risk for rejection. Hyperglycemia increases the co-
timulation and presentation of antigens, and increases
schemic damage29 and the inﬂammatory reaction associ-
ted with reperfusion;30 it increases cytokine production
nd adhesion molecule expression, as well as dendritic cell
ctivation.31,32
Some observational studies have evaluated the impact of
iabetes on patient survival and the risk for complications
n the immediate post-transplantation period,26,33 whereas
thers have reported an association between hyperglycemia
uring the intraoperative period and the risk for postopera-
ive infection and mortality at the ﬁrst year follow-up.34,35
owever, none of the studies took metabolic control into
ccount during the immediate post-transplantation period;
hat has only been evaluated in patients that underwent
one marrow or kidney transplantation.36--39
Based on the above, we decided to conduct an observa-
ional study to determine whether there was an association
etween the increased glucose values during the ﬁrst 48 h
fter liver transplantation and the risk for early rejection,
acterial infection, or longer hospital stay. Our hypothesis
as that the presence of sustained hyperglycemia during
hat period of time was associated with a greater risk for
arly rejection, a higher risk for nosocomial infection, and
onger hospital stay.
ethods
tudy design and population
retrospective cohort study was designed analyzing all the
ecords of the patients that underwent liver transplanta-
ion within the time frame of 2006 and 2011 at the Hospital
ablo Tobón Uribe, a highly specialized university hospital
nd transplantation center in the city of Medellin, Colom-
ia. We included patients above the age of 15 years that
ad at least one glucose measurement within the ﬁrst 48 h
fter transplantation and excluded all the patients that died
s a consequence of surgical complications within the ﬁrst
4 h, posttransplantation.
easurements
ll the glucose measurements recorded within the ﬁrst
8 h after transplantation from the time of the patient’s
dmittance into the ICU were documented. Three different
easurements were used for determining hyperglycemia:
) at least one value > 140mg/dl, b) the mean or median
f all measurements > 140mg/dl, and c) the time-weighted
equivalent of an area under the curve of all the measure-
ents) glucose value > 140mg/dl. A linear relation between
he measurement values was assumed for the latter, with
ntervals of 2 hours or more, and the result was the percent-
ge of time during the ﬁrst 48 h posttransplantation in which
he patient had glucose values > 140mg/dl.40 The patients
ere differentiated according to a history of diabetes mel-
itus. Infection was established as conﬁrmed or probable
ithin the ﬁrst 30 posttransplantation days in accordance
ith the Center for Diseases Control (CDC) deﬁnitions41 and
ith the medical history records. Early acute cellular rejec-
ion of the liver allograft was deﬁned by the medical team
(
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n charge of the treatment of those patients in whom bio-
hemical abnormalities accompanied by histologic rejection
hanges were detected in the ﬁrst 90 days after transplan-
ation. Nosocomial mortality was deﬁned as the death of
patient during hospitalization that was not related to
omplications inherent in the surgical procedure.
Among the confounding variables of risk for graft rejec-
ion were the prior sensitization according to the presence
f preformed antibodies directed at the anti-HLA major
istocompatibility complex (MHC) recorded in the medical
istory, the commencement of treatment with calcineurin
nhibitors 72 h after liver transplantation, and the condition
hat led the patient to require a transplant; alcoholic, cryp-
ogenic, viral, or autoimmune cirrhosis, or other causes. The
onfounding variables regarded as risk for infection were the
se of parenteral nutrition, ICU stay, the need for transfusion
fter transplantation,42 age, and female sex.43
nalysis plan
he continuous variables were presented as medians with
nterquartile ranges or as means with standard deviation.
he nominal variables were presented as proportions with
onﬁdence intervals. The association between the dichoto-
ous variables was explored through the chi-square test or
he Fisher exact test in accordance with the expected value
f the cells, and the association magnitude was established
hrough an indirect relative risk (odds ratio) obtained by
eans of the Woolf approximation with a 95% conﬁdence
nterval. The association between the continuous variables
as explored using the Student’s t test, assuming unequal
ariances.
esults
he data of 316 patients that underwent liver transplanta-
ion were collected; 152 patients were excluded from the
nalysis due to a lack of glucose results at 48 h after trans-
lantation (n = 142) and to death during the procedure or in
he immediate postoperative period (n = 10). The proportion
f rejections in the excluded patients was 10.5% (n = 16).
f the 164 patients analyzed, 108 (66%) were men and the
ean age was 51± 12.3 years. Table 1 shows the general
opulation information.
According to the established deﬁnitions, 94% of the
atients analyzed presented with at least one form of hyper-
lycemia: a minimum of one value above 140mg/dl in
54 patients and the mean of all the measurements >
40mg/dl in 140 patients. The mean glucose level at the
ime of ICU admission was 182± 55mg/dl and the patients
nalyzed had glucose levels above 140mg/dl for an average
0% of the ﬁrst 48 h. In the bivariate analysis, hyper-
lycemia was not associated with a greater risk for rejection,
nfection, or longer hospital stay, regardless of its deﬁni-
ion (table 2). The results did not vary in the analysis of
hose patients with no history of diabetes or those that
ad more than one glucose measurement in the ﬁrst 48 h
tables 3 and 4). None of the factors regarded as potential
onfounding variables (late commencement of calcineurin
nhibitors, HLA histocompatibility, the reason for transplan-
ation, sex, age, the need for transfusion, the use of total
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Table 1 General population characteristics.
Variable n = 164
Age (range) 51± 12.3 (15-70)
Sex, n (%)
Men 108 (65.8%)
Diabetes mellitus
History of diabetes
mellitus, n (%)
48 (28%)
Development of
posttransplantation
diabetes, n (%)
35 (30%)
Hospital stay in days
(range)
20± 19.9 (4-139)
ICU stay in days (range) 5.5± 9.1 (1-100)
TPN use (percentage),
n (%)
13 (8%)
Red blood cell
transfusion
(percentage), n (%)
120 (74%)
Late calcineurin
inhibitor
commencement, n (%)
12 (7.3%)
Cause of transplantation, n (%)
Alcoholic cirrhosis 33 (20%)
Cryptogenic cirrhosis 23 (14%)
Viral hepatitis (B and C
viruses)
33 (20%)
Autoimmune hepatitis 33 (20%)
Others 42 (25,6%)
Meld (range) 18.6± 5.5 (8-39)
Immunosuppression
Steroids 164 (100%)
Azathioprine 152 (92.6%)
Ciclosporin 158 (96.3%)
Early acute cellular
rejection, n (%)
33 (20%)
Infection, n (%) 12 (7.3%)
Urinary infection 4
Pneumonia 4
Abdominal infection 2
Phlebitis 1
Fungemia 1
Death, n (%) 26 (16%)
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sICU: intensive care unit; MELD: model for end-stage liver dis-
ease; TPN: total parenteral nutrition.
parenteral nutrition [TPN], or length of stay in the ICU) were
associated with the risk for rejection or infection (data not
shown).
No greater risk for infection (OR 2.3; 95% CI = 0.48-10.9)
or difference in the length of hospital stay (20.7 days vs
19 days) was found in the diabetic patients when com-
pared with the non-diabetic ones. The proportion of diabetic
patients on the transplantation waiting list was high (28%),
and the quantity of patients that developed diabetes after
transplantation was considerable (30%).
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iscussion
n our study, we attempted to clarify whether hyper-
lycemia, deﬁned either as an isolated, mean, or
ime-weighted value, was associated with a greater risk
or rejection, infection, or longer hospital stay. Our results
howed that a large proportion of patients that underwent
iver transplantation presented with some degree of hyper-
lycemia during the ﬁrst 48 h after transplantation and that
n important number of those patients had elevated glucose
alues for the majority of that period. However, those high
lucose values, whether isolated, mean, or weighted, were
ot associated with a higher risk for infection, rejection, or
onger hospital stay. In addition, when a history of diabetes
as taken into consideration, no greater risk for infection
uring the postoperative period was found.
According to previous studies on animal models and
ome clinical observations, hyperglycemia is associated with
mmune and non-immune alterations that could increase the
isk for rejection or infection in transplantation patients.
hese include a greater inﬂammatory response associated
ith reperfusion-related ischemia, which appears to be
ediated by an exaggerated adhesion of leukocytes to the
ndothelium.30,44 Furthermore, hyperglycemia in the post-
perative period reﬂects an insulin-resistant state, which
s associated with higher alpha tumor necrosis factor and
nterleukin 1, 6, and 12 values; all of this favors a state
f systemic inﬂammation that could increase the immuno-
ogic response against the graft.45 Finally, the elevated
lucose levels increase the expression of the major his-
ocompatibility complex class I and class II molecules,
ith the subsequent potential increase of the innate
mmune response activation mechanisms.46 From the clin-
cal viewpoint, in an analysis carried out on 184 patients
hat evaluated intraoperative glucose levels,34 the authors
eported that values above 150mg/dl were associated with
greater risk for infection at 30 days following surgery, as
ell as with a higher mortality rate at one year.
Multiple studies have also been conducted evaluating the
mpact that hyperglycemia has on hospitalized patients. In
published study by Umpierrez et al.13 in which hyper-
lycemia was deﬁned according to its isolated values, it was
ssociated with longer hospital stay. In another study14 that
lso considered the isolated values in the immediate postop-
rative period, hyperglycemia was associated with a 5-fold
reater risk for presenting with nosocomial infections. When
he outcomes of critically ill hospitalized patients have been
valuated, taking into account the length of time glucose
evels remained high, it was found that there could be a
eneﬁt in relation to mortality if the values stayed within a
44-200mg/dl range.40 The proportion of diabetic patients
n the transplantation waiting list was high in our study, a
esult that has also been described in other case series.22 Our
esults showed that a considerable number of nondiabetic
atients developed diabetes mellitus after transplanta-
ion, which was also similar to data described in other
tudies.23
The majority of studies that have evaluated glycemia
n hospitalized patients usually deﬁne it as one or several
alues that are altered at one period of time. However,
t is important to consider not only isolated or mean val-
es, but also the length of time during which the patient
184 C.E. Builes Montan˜o et al.
Table 2 Association between acute rejection, nosocomial infection, or length of hospital stay and the different deﬁnitions of
hyperglycemia (n = 164).
Variable Deﬁnition 1 Deﬁnition 2
Rejection OR 0.56 (95% CI 0.14-2.11) OR 0.55 (95% CI 0.21-1.43)
Infection OR 0.71 (95% CI 0.10-4.99) OR 0.85 (95% CI 0.20-3.67)
Mean hospital staya 3.56 (95% CI --7.77-14.90) 3.90 (95% CI --4.16-11.96)
Deﬁnition 3
Rejection 8.05 (95% CI --0.31-16.42)
Infection 6.57 (95% CI --13.30-26.46)
Mean hospital staya --4.42 (95% CI --1.71-2.32)
Hyperglycemia deﬁnitions: 1) at least one value > 140 mg/dl, 2) mean of all the measurements > 140 mg/dl), and 3) time-weighted
value.
a Expressed as difference of means.
Table 3 Association between acute rejection, nosocomial infection, or length of hospital stay and the different deﬁnitions of
hyperglycemia in non-diabetic patients (n = 116).
Variable Deﬁnition 1 Deﬁnition 2
Rejection OR 0.70 (95% CI 0.12-3.86) OR 0.56 (95% CI 0.19-1.66)
Infection OR 0.54 (95% CI 0.05-4.9) OR 0.76 (95% CI 0.14-3.9)
Mean hospital staya 4.80 (95% CI --12.4-21.9) 5.12 (95% CI --5.1-15.3)
Deﬁnition 3
Rejection 6.27 (95% CI --1.6-14.16)
Infection 16.6 (95% CI 10.95-22.2)
Mean hospital staya --6.4 (95% CI --16.0-3.4)
ean o
p
i
t
c
n
a
4
t
e
t
e
t
i
r
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a Expressed as difference of means.
resents with the elevated glucose levels; such differences
n the type of measurement could partially explain the con-
radictory results of studies that have included glycemic
ontrol.40,47--51
One of the important limitations of our study was the high
umber of patients that were excluded for not having an
dequate register of glucose measurement during the ﬁrst
8 h after transplantation and the subsequent reduction in
he sample size necessary for detecting differences. Nev-
rtheless, all the hyperglycemia measurements appeared
f
a
t
Table 4 Association between acute rejection, nosocomial infect
hyperglycemia in those patients with more than one glucose meas
Variable Deﬁnition 1
Rejection OR 0.31 (95% CI 0.06
Infection OR 0.48 (95% CI 0.05
Mean hospital staya 5.1 (95% CI --12.
Rejection
Infection
Mean hospital staya
Hyperglycemia deﬁnitions 1) at least one value > 140mg/dl, 2) mean o
a Expressed as difference of means.f all the measurements > 140 mg/dl), and 3) time-weighted value
o favor it as a «protective factor» in relation to adverse
vents and the proportion of rejections was even lower in
he patients not included in the analysis (10% vs 20%). An
mportant strength of our study was the detailed explo-
ation of the exposure variable, with the different manners
n which hyperglycemia was deﬁned; not only did we look
or an association with isolated values, but we also took into
ccount the length of time the glucose values remained high.
Despite the limitations that correspond to an observa-
ional study in terms of residual confounding and population
ion, or length of hospital stay and the different deﬁnitions of
urement in the ﬁrst 48 hours (n = 153).
Deﬁnition 2
-1.49) OR 0.44 (95% CI 0.16-1.21)
-4.43) OR 0.77 (95% CI 0.15-3.83)
2-22.5) 4.5 (95% CI --4.5-13.7)
Deﬁnition 3
8.9 (95% CI 0.26-17.5)
8.6 (95% CI --11.2-28.5)
--4.9 (95% CI --11.7-1.79)
f all the measurements > 140mg/dl) and 3) time-weighted value
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type, this analysis showed that hyperglycemia is most
likely a frequent phenomenon in the immediate postoper-
ative period of patients that undergo liver transplantation,
and that complications like those of rejection and infec-
tion essentially depend on other factors, such as the use
of immunosuppressant drugs, histocompatibility, and age,
among others. A clinical trial could conﬁrm whether carrying
out some form of metabolic control in liver transplantation
patients would provide any beneﬁt in relation to rejection
or infection. However, in patients that underwent kidney
transplantation and had strict glycemic control, the risks
appear to be greater than the beneﬁts,39 and in critically ill
patients in the ICU, kidney transplantation appears to bring
about a high risk for hypoglycemia and a higher mortality
rate.51 Previous ﬁndings and the results of our study suggest
that glycemic control contributes very little in relation to
complications in liver transplantation patients.
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Annex 1. Immunosuppression regimen used
at the institution
a) Corticosteroids
Methylprednisolone 500mg i.v. in the anhepatic stage,
and continued in the postoperative period as follows:
- Day 1: methylprednisolone 200mg, i.v., at 4 doses of
50mg/6 h.
- Day 2: methylprednisolone 160mg, i.v., at 4 doses of
40mg/6 h.
- Day 3: methylprednisolone 120mg, i.v., at 4 doses of
30mg/6 h.
- Day 4: methylprednisolone 80mg, i.v., at 2 doses of
40mg/12 h.
- Day 5: methylprednisolone 40mg, i.v., at one dose.
- Starting at day 6: oral prednisone at a dose of 20mg/day
in the mornings.
b) Azathioprine
1-2mg/kg from the immediate posttransplantation
period through a nasogastric tube and then orally. In the
case of renal dysfunction or any other contraindication for
the use of a calcineurin inhibitor, mycophenolate 1.5 g v.o.
every 12 h is indicated.
c) Calcineurin inhibitors
Ciclosporin or tacrolimus: they are begun once the
patient is hemodynamically stable with good diuresis and
no renal dysfunction.The medication of choice is ciclosporin v.o. or via gastric
tube at increasing doses until reaching therapeutic levels
(see below) or presenting with side effects.
d) Induction therapy
1patients 185
Only basiliximab or daclizumab are used in patients with
reoperative renal dysfunction or in patients that undergo
iver or kidney transplantation. Two doses are placed, one
n the ﬁrst 6 h posttransplantation, and the other on post-
ransplantation day 3.
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